COMPANY
Kardigan
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Vice President, Global Program Head | Princeton, New Jersey, United States | Oct 21, 2026 | Oct 22, 2026 |
| Director, PV Scientist | Princeton, New Jersey, United States | Oct 20, 2026 | Oct 21, 2026 |
| Contracts Manager (Prolaio) | Chicago, IL | Oct 14, 2026 | Oct 16, 2026 |
| Medical Director, Clinical Development | Princeton, New Jersey, United States | Oct 13, 2026 | Oct 16, 2026 |
| Executive Director, Global Program Manager | Princeton, New Jersey, United States | Oct 12, 2026 | Oct 16, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07771465, actual start Aug 26, 2026); since then posted 6 clinical-operations roles. ClinicalTrials.gov NCT07771465 (Aug 26, 2026)
Evidence (1 event)
- Aug 26, 2026 · ClinicalTrials.gov NCT07771465
leadSponsor.name='Kardigan, Inc.'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-08-18; briefTitle='A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy'
- Aug 26, 2026 · ClinicalTrials.gov NCT07771465
Timeline
- Trial start Phase 3: A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy source ↗
- Trial start Phase 2: Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension source ↗
- Trial start Phase 2/Phase 3: A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy source ↗
- Trial start Phase 2/Phase 3: Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study source ↗
- Trial start Phase 2: A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) source ↗
Upcoming milestones
- 2026-12 (ESTIMATED) · Phase 2 · Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension · NCT07511361
- 2027-09 (ESTIMATED) · Phase 2/Phase 3 · A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy · NCT07210723
- Aug 31, 2028 (ESTIMATED) · Phase 2/Phase 3 · Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study · NCT07001800
- 2032-11 (ESTIMATED) · Phase 3 · A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy · NCT07771465
Clinical trials (lead sponsor) 5
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07210723 | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Phase 2/Phase 3 | Recruiting | Feb 13, 2026 | 2027-09 (estimated) |
| NCT07771465 | A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Phase 3 | Recruiting | Aug 26, 2026 | 2032-11 (estimated) |
| NCT07511361 | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | Phase 2 | Recruiting | Jun 23, 2026 | 2026-12 (estimated) |
| NCT07001800 | Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/Phase 3 | Recruiting | Jun 27, 2025 | Aug 31, 2028 (estimated) |
| NCT06864104 | A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) | Phase 2 | Completed | Apr 10, 2025 | Jan 12, 2026 (actual) |
Raises and investors new
- InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗
Open jobs 28
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Vice President, Global Program Head | Princeton, New Jersey, United States | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Director, PV Scientist | Princeton, New Jersey, United States | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Contracts Manager (Prolaio) | Chicago, IL | Oct 14, 2026 | Oct 16, 2026 | Senior |
| Medical Director, Clinical Development | Princeton, New Jersey, United States | Oct 13, 2026 | Oct 16, 2026 | Executive |
| Executive Director, Global Program Manager | Princeton, New Jersey, United States | Oct 12, 2026 | Oct 16, 2026 | Executive |
| Director, Clinical Quality Lead | South San Francisco, California, United States, Princeton, New Jersey, United States | Oct 6, 2026 | Oct 16, 2026 | Senior |
| Senior Director, Biostatistics | Princeton, New Jersey, United States | Oct 6, 2026 | Oct 16, 2026 | Senior |
| Senior Director, Clinical Operations Program Lead | Princeton, New Jersey, United States | Oct 5, 2026 | Oct 16, 2026 | Senior |
| Senior Contracts Manager, Clinical Agreements | Princeton, New Jersey, United States | Sep 30, 2026 | Oct 16, 2026 | Senior |
| Senior Director, Head of Statistical Programming | Princeton, New Jersey, United States | Sep 25, 2026 | Oct 16, 2026 | Executive |
| Manager, Forecasting | Evanston, Illinois, United States | Sep 23, 2026 | Oct 16, 2026 | Mid |
| Manager, Accounting | Princeton, New Jersey, United States | Sep 15, 2026 | Oct 16, 2026 | Senior |
| Executive Director, Regulatory Strategy | Princeton, New Jersey, United States | Sep 14, 2026 | Oct 16, 2026 | Executive |
| Senior Director, Product Strategy | Princeton, New Jersey, United States | Sep 11, 2026 | Oct 16, 2026 | Senior |
| Sr. Director, Clinical Trial Optimization | Princeton, New Jersey, United States | Sep 11, 2026 | Oct 16, 2026 | Senior |
| Director, Technical Operations Demand/Supply Planning | South San Francisco, California | Sep 4, 2026 | Oct 16, 2026 | Senior |
| Scientist, Drug Metabolism and Pharmacokinetics (DMPK) | South San Francisco, California, United States | Sep 3, 2026 | Oct 16, 2026 | Entry |
| Director, Clinical Trial Liaison - West | Remote - United States | Sep 1, 2026 | Oct 16, 2026 | Senior |
| Head of Medical Affairs | Princeton New Jersey | Aug 25, 2026 | Oct 16, 2026 | Executive |
| Director, Field Medical / Medical Science Liaison - New England | Boston, MA (Field-based, New England region) | Aug 11, 2026 | Oct 16, 2026 | Senior |
| Director, Field Medical/Medical Science Liaison - Tri-State | Princeton, NJ; New York, NY; Philadelphia, PA (Field-based, Tri-State region) | Aug 10, 2026 | Oct 16, 2026 | Senior |
| Director, Field Medical/Medical Science Liaison - North Central | Chicago, IL or St. Paul, MN (Field-based, North Central region) | Aug 10, 2026 | Oct 16, 2026 | Senior |
| Senior Manager, SEC Reporting & Technical Accounting | Princeton, New Jersey, United States, South San Francisco, California, United States | Aug 3, 2026 | Oct 16, 2026 | Senior |
| Executive Director, People & Culture Business Partner | South San Francisco, California, United States | Jul 31, 2026 | Oct 16, 2026 | Executive |
| Senior Director, Clinical Pharmacology | South San Francisco, California, United States, Princeton, New Jersey, United States | Jul 20, 2026 | Oct 16, 2026 | Senior |
| Sr. Manager, Clinical Trial Lead | Princeton, New Jersey | Jun 29, 2026 | Oct 16, 2026 | Senior |
| Vice President, Clinical Development | Princeton, New Jersey, United States | Jun 24, 2026 | Oct 16, 2026 | Executive |
| Senior Manager, Financial Planning & Analysis | South San Francisco, California, United States, Princeton, New Jersey, United States | Jun 22, 2026 | Oct 16, 2026 | Senior |
Connect
See your connections at Kardigan on LinkedIn (search by name, results not checked)